Lenvatinib Mesylate

Lenvatinib is a kinase inhibitor that is indicated:

  • For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).
  • In combination with everolimus, for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior antiangiogenic therapy.
  • For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).

There are no products to list in this category.

Continue